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Human Papillomavirus Vaccination
and School Entry Requirements
Politically Challenging, but Not Impossible
Anogenital and oropharyngeal cancers that are attrib-
uted to oncogenic strains of the human papillomavirus
(HPV) number approximately 31 500 per year in the
United States (https://www.cdc.gov/cancer/hpv/
statistics/cases.htm), and despite the availability of a safe
and effective HPV vaccine that protects against these
strains, the United States has a disappointing record of
vaccine uptake after more than a decade of promoting
the vaccine for adolescents.
To date, national strategies to improve HPV vac-
cine uptake have centered primarily on health care cli-
nicians (pediatricians, obstetrician-gynecologists, and
family practice physicians) and campaigns to encour-
age and train primary care practitioners on HPV vacci-
nation; the returns on these campaigns have been mod-
est. Data from 2016 showed that 60.4% of adolescents
aged 13 to 17 years received at least 1 dose of the vac-
cine, and only 43.4% of adolescents were up to date with
the vaccine.1 Focusing solely on individual- and inter-
personal-level strategies (ie, the medical clinician and the
parent) limits the opportunity to reach the level of HPV
vaccine coverage that is desired in the United States and
that has been achieved by other nations that have de-
veloped successful HPV immunization programs, such
as Australia, Canada, and the United Kingdom.
After more than a decade of promoting a strategy
that is not sufficient, additional approaches to improv-
ing vaccine uptake should be considered. One of the
most obvious tactics would be promoting and imple-
menting state-level school entry requirements for the
HPV vaccine along with other adolescent vaccines, such
as the tetanus-diphtheria-pertussis vaccine, that al-
ready are required for middle school entry in most
states.2 However, discussions related to including HPV
vaccine school entry requirements at a policy level are
not only rare, but are also often overlooked, such as in
the case of the 2014 report of the President’s Cancer
Panel.3 The panel described the low vaccine rates and
recommended 3 goals for increasing rates in the United
States that focused on clinician-based vaccination strat-
egies, such as developing communication programs that
are associated with the HPV vaccine for physicians. There
is a brief mention of school-based and school-located
programs, which have been successful in other coun-
tries, but the panel concluded that there are too many
barriers to implementing those programs in the United
States. However, there was a caveat that stated “Fur-
thermore, if vaccination rates in the United States do not
improve dramatically over the next several years, the fea-
sibility of school-located vaccination should be
reexamined.”3
Limiting discussions to only school-located pro-
grams does not encompass the broader approach of
implementing school entry requirements for HPV vac-
cination, which still involves the same interaction
between parents and health care clinicians. In fact, a
school-entry approach has the added “incentive” for both
parents and clinicians that the vaccine is now required
before beginning middle school. At the time of the Presi-
dent’s Cancer Panel report, there had been limited suc-
cess with HPV vaccine school entry policies, and until the
recent program enacted in Rhode Island in 2015, it would
have been difficult to provide an evidence-based argu-
ment for adding these policies to the broader strate-
gies. Virginia and the District of Columbia instituted ear-
lier policies in 2008 and 2009, respectively, but with
generous opt-out provisions and, in the case of Vir-
ginia, no consequences for nonvaccination. Not surpris-
ingly, these policies were not particularly effective, dem-
onstrating that l imited policies do not work.4
Furthermore, evidence with other vaccines shows that
broadening opt-out provisions leads to lower vaccina-
tion rates and outbreaks of vaccine-preventable
infections.5 However, the Rhode Island program re-
quires HPV vaccine initiation before seventh grade, is
gender-neutral, and has also implemented a more re-
strictive exemption strategy to opt out of vaccinations
than previous programs, such as the one implemented
in Virginia.6 Results of the Rhode Island initiative are im-
pressive, with a vaccination initiation rate of 90% and
88% among girls and boys, respectively,1 and an in-
creased predicted vaccine initiation rate of 11% among
adolescent boys compared with boys in other states af-
ter the policy implementation.7 No similar change was
found for girls in Rhode Island, as the vaccination rate
was already high, which was likely the result of a “ceil-
ing effect” of an already impressive vaccine program.
However, replicating this approach of gender-neutral
school entry has the potential to improve uptake over-
all and may help ameliorate gender disparities in vacci-
nation.
Promoting school entry campaigns on a state-by-
state basis may seem daunting, but 2 factors may miti-
gate that concern: the continued efforts to improve the
current strategy of clinician recommendation and the
successful efforts, such as the Rhode Island program,
that may encourage vaccine coalitions in other states to
promote similar programs. At present, statewide ef-
forts may lack the collaborative political will to pursue
HPV vaccine school entry requirements, but supple-
menting the current efforts is critical. Depending solely
on clinician recommendations for the HPV vaccination
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has proven insufficient. Unlike clinician rates for required vaccines,
which exceed 80%, the rates of HPV vaccination are both lower and
inconsistent.1 Moreover, clinician recommendations and school en-
try requirements can be complementary HPV vaccination ap-
proaches. When school entry vaccination becomes a policy, it
removes the burden from the clinician to recommend the vaccine
and encourages parents to vaccinate their children. These 2
approaches would act complementarily with one another.
So what is the way forward? First, get the critical medical pro-
fessional organizations, such as the American Medical Association,
the American Academy of Pediatrics, the American College of
Obstetricians and Gynecologists, and the American Academy of Fam-
ily Physicians, to endorse a move toward school entry require-
ments for HPV vaccination. Commendations from these groups will
provide the needed reassurance to parents and clinicians that this
vaccine is as important and necessary as any other vaccine that their
child receives. Second, identify stakeholders statewide, including lo-
cal vaccine coalitions, who can work together with policy makers to
implement a state-level school entry requirement. This effort to cre-
ate the political will that is necessary for a new policy is critical and
would also act to reassure parents and clinicians.
What we do know is that when school entry programs are imple-
mented correctly in the United States, they work well. Despite the
barriers to instituting school entry requirements, we should not stop
promoting them just because it is a challenging task. To paraphrase
the President’s Cancer Panel of 2014, vaccination rates in the United
States have not improved dramatically in the past several years since
that report was written. Thus, reexamining strategies that are as-
sociated with school-based and school entry programs is overdue.
There is evidence that school entry requirements can be effective
tools in complementing the existing clinician-focused approach. To
protect children from preventable cancers, such as those caused by
HPV, we need a robust, multilayered plan that includes ongoing re-
search into public opinions about the vaccine and school entry re-
quirements and the development of effective strategies to commu-
nicate with the public about the value of HPV vaccine school entry
requirements for promoting personal and public health. In addi-
tion, the promotion of school entry requirements should include
strict opt-out provisions that are similar to other vaccines, contin-
ued training and implementation programs for health care clini-
cians, and messaging campaigns to encourage parents to vacci-
nate their children against HPV.
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